Head and Neck Cancer Stem Cells: The Side Population

The Laryngoscope (Impact Factor: 2.03). 03/2011; 121(3):527 - 533. DOI: 10.1002/lary.21032

ABSTRACT Objectives/Hypothesis:The cancer stem cell (CSC) theory concludes that a subpopulation of cancer cells, the cancer stem cells, can self-renew and are responsible for tumor growth. Previous studies have identified cells able to efflux Hoechst 33342 dye as the side population (SP). SP cells and CSCs share many characteristics, suggesting the SP isolated from malignant tumors contains CSCs.Study Design:Experimental Study.Methods:The SP was isolated from a head and neck cancer cell line and analyzed for CSC-like characteristics.Results:The SP demonstrated the ability to reproduce both SP and non-side population (NSP) cells from as few as one cell. The SP had lower expression of active β-catenin and more resistance to 5-fluorouracil; the SP also demonstrated greater expression of Bmi-1 (4.3-fold) and ABCG2 (1.4-fold). SP cells were able to produce tumors in an animal model, whereas NSP were not. SPs were identified in two primary human tumors.Conclusions:This work adds to the evidence that the SP in head and neck cancer represents cells with CSC properties and provides a method by which CSCs can be isolated and studied. Laryngoscope, 2011

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Head and neck squamous cell carcinoma (HNSCC) is one of the world top ten most common cancers with its highest occurrence in the Indian subcontinent and different aggressive and etiological behavioural patterns. The scenario is only getting worst with the 5 year survival rates dropping to 50%, persistent treatment failures and frequent cases of relapse/recurrence. One of the major reasons for these failures is the presence of cancer stem cells (CSCs), a small population of cancer cells that are highly tumourigenic, capable of self-renewal and have the ability to differentiate into cells that constitute the bulk of tumours. Notably, recent evidence suggests that cancer stem cells are especially resistant to conventional therapy and are the "drivers" of local recurrence and metastatic spread. Specific markers for this population have been investigated in HNSCC in the hope of developing a deeper understanding of their role in oral cancer pathogenesis, elucidating novel biomarkers for early diagnosis and newer therapeutic strategies. This review covers the fundamental relevance of almost all the CSC biomarkers established to date with a special emphasis on their impact in the process of oral tumourigenesis and their potential role in improving the diagnosis, prognosis and treatment of OSCC patients.
    Asian Pacific journal of cancer prevention: APJCP 11/2014; 15(20):8549-56. DOI:10.7314/APJCP.2014.15.20.8549 · 1.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background The identification of cancer stem cells (CSCs) in laryngeal cancer remains a dilemma. Our previous studies identified CD133(+) subgroup and side population (SP) cells in the laryngeal cancer cell line, human epithelial type-2 (Hep-2). Although both cell types shared some tumor-initiating properties, they were heterogeneous. In this study, we further enriched CSCs from this cell line. Methods We divided the SP cells into CD133(+)SP and CD133(-)SP cells by combining SP and CD133, and compared CSC-associated properties between the 2 subgroups. ResultsSP cells contained CD133(+)SP and CD133(-)SP, and CD133(+)SP cells manifested preferential expression of self-renewal genes, higher capacity for proliferation, differentiation, and clone and spheroid formation, enhanced resistance to radiation and chemotherapy, and greater tumorigenicity compared with CD133(-)SP cells. Conclusion The CD133(+)SP subpopulation is enriched in CSCs compared with the CD133(-)SP subgroup, suggesting that the combination of SP and CD133 can further purify CSCs in the Hep-2 cell line. © 2013 Wiley Periodicals, Inc. Head Neck, 2013
    Head & Neck 11/2013; 36(9). DOI:10.1002/hed.23447 · 3.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer stem cells (CSC) and genes have been linked to cancer development and therapeutic resistance, but the signaling mechanisms regulating CSC genes and phenotype are incompletely understood. CK2 has emerged as a key signal serine/threonine kinase that modulates diverse signal cascades regulating cell fate and growth. We previously showed that CK2 is often aberrantly expressed and activated in head and neck squamous cell carcinomas (HNSCC), concomitantly with mutant (mt) tumor suppressor TP53, and inactivation of its family member, TAp73. Unexpectedly, we observed that classical stem cell genes Nanog, Sox2, and Oct4, are overexpressed in HNSCC with inactivated TAp73 and mtTP53. However, the potential relationship between CK2, TAp73 inactivation, and CSC phenotype is unknown. We reveal that inhibition of CK2 by pharmacologic inhibitors or siRNA inhibits the expression of CSC genes and side population (SP), while enhancing TAp73 mRNA and protein expression. Conversely, CK2 inhibitor attenuation of CSC protein expression and the SP by was abrogated by TAp73 siRNA. Bioinformatic analysis uncovered a single predicted CK2 threonine phosphorylation site (T27) within the N-terminal transactivation domain of TAp73. Nuclear CK2 and TAp73 interaction, confirmed by co-immunoprecipitation, was attenuated by CK2 inhibitor, or a T27A point-mutation of this predicted CK2 threonine phospho-acceptor site of TAp73. Further, T27A mutation attenuated phosphorylation, while enhancing TAp73 function in repressing CSC gene expression and SP cells. A new CK2 inhibitor, CX-4945, inhibited CSC related SP cells, clonogenic survival, and spheroid formation. Our study unveils a novel regulatory mechanism whereby aberrant CK2 signaling inhibits TAp73 to promote the expression of CSC genes and phenotype.
    Neoplasia (New York, N.Y.) 10/2014; 16(10):789–800. DOI:10.1016/j.neo.2014.08.014 · 5.40 Impact Factor